Sumerian

Sumerian Discovery is a biotechnology company focused on the identification and development of small molecule therapeutics for biological targets historically considered "undruggable." The company utilizes a proprietary discovery platform designed to uncover novel binding pockets and mechanisms of action, including RNA-targeting and protein degradation approaches. Led by a team of veteran drug hunters from major pharmaceutical organizations like AbbVie, Sumerian Discovery targets high-value pathways in oncology and immunology. The firm is currently in the pre-clinical stage, advancing a pipeline of internal programs while exploring strategic opportunities. Headquartered in Cambridge, MA, the company is supported by leading life science venture capital investors including ARCH Venture Partners and Northpond Ventures.